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Few large prospective studies of adverse reactions after bacille Calmette-Gue´rin (BCG) vaccination are available.
In a prospective national study of such adverse reactions among 918 subjects (aged 1 day to 54 years) over a
14-month period, 45 vaccinees (5%) reported 53 adverse reactions (23 injection-site abscesses, 14 severe local
reactions, 10 cases of lymphadenitis, and 6 other reactions). Only 1% of vaccinees required medical attention.
Reactions, particularly lymphadenitis, were significantly less common in infants !6 months old (but not in
subjects aged 6 months) vaccinated by trained (vs. untrained) providers (relative risk [RR], 0.24; 95%
confidence interval [CI], 0.09–0.68). Injection-site abscesses (RR, 2.96; 95% CI, 1.11–7.90) and severe local
reactions (RR, 4.93; 95% CI, 1.11–21.90) were significantly more common in older vaccinees. Local reactions
were more frequently reported by adult females than by adult males (RR, 7.18; 95% CI, 1.59–32.45). Adverse
reactions were not significantly associated with any currently available vaccine batch, previous receipt of BCG
vaccine, or concomitant administration of other vaccines.
BCG vaccine has been used for routine vaccination
against tuberculosis for nearly 80 years. Despite its
modest efficacy [1, 2], the vaccine has been used in
180% of the world’s population [3]. In Australia, child-
hood BCG vaccination was discontinued in the 1980s,
and vaccination is currently recommended only for
those individuals at high risk of exposure to tubercu-
losis, including Aboriginal or Torres Strait Islander ne-
onates living in regions of high incidence; children aged
!5 years who will be traveling to live in countries with
a high tuberculosis prevalence or who live in house-
holds with migrants or visitors from countries with a
high incidence of the disease; health care workers in
certain occupational areas; and travelers aged 15 years
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who will spend prolonged periods in countries with a
high prevalence of tuberculosis [4].
Serious adverse reactions after BCG vaccination are
rare, occurring in association with !1 in 1 million doses
[5]. Although local and regional adverse reactions occur
most frequently, the majority are self-limiting. Varia-
tions in the frequency of adverse reactions have been
reported and are attributed to a number of factors,
including dose and strain of vaccine, age and immune
status of the vaccinee, and technique of vaccine ad-
ministration [5].
In Australia, an increase in adverse reactions to BCG
[6] was reported from one region after there was a
change in the national supply of BCG vaccine in mid-
July 1996. At this time, the BCG vaccine produced by
CSL Vaccines (derived from the New York strain;
7– 5 cfu per 0.1 mL, with lactose stabilizer) was15 10
replaced by a Connaught vaccine derived from the
Montreal strain (8– 5 cfu/mL with monosodium32 10
glutamate stabilizer). In response to the regional report,
national active surveillance was established from No-
vember 1998 through April 2000 to determine the in-
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cidence and nature of BCG reactions in a consecutive sample
of vaccine recipients.
METHODS
Study population. Administering BCG vaccinations on a fre-
quent basis centers in all Australian states or territories were
invited to participate in the study. The geographic distribution
of vaccine recipients in the study sample was related to the
distribution of BCG providers rather than to regional popu-
lation size. Providers were asked to enroll consecutive BCG
vaccinees and to record information at the time of vaccination,
including the patient’s age, sex, and ethnicity, previous receipt
of a tuberculin skin test, the clinic setting, the BCG vaccine
dose administered, vaccine batch, and the training of the pro-
vider. Standard data collection forms were used. Providers were
also asked to record whether they had been specifically trained
to administer the vaccine. Deidentified data for all enrolled
vaccinees were forwarded for entry and analysis. Where pos-
sible, investigators confirmed the written reports of adverse
reactions and their management by discussion with the pro-
vider who reported them.
Vaccine and administration. The vaccine used during the
study was the Connaught (Montreal strain) freeze-dried, live
BCG vaccine. When reconstituted with PBS, each 0.1 mL of
vaccine contains 8– 5 cfu and monosodium glutamate32 10
1.5% as a stabilizer. The vaccine is recommended to be given
via intradermal injection (Connaught product information, dis-
tributed by CSL, Melbourne, Australia).
Case identification. Adverse reactions were detected by
active case patient–finding by health care providers (by tele-
phone or in a face-to-face interview) at 2–4 weeks and again
at 16–18 weeks after vaccination. Vaccinees were also encour-
aged to report any adverse reactions to their provider during
this time.
Adverse reactions. Adverse reactions were classified, ac-
cording to World Health Organization definitions [7], as in-
jection-site abscess, lymphadenitis, severe local reaction, and
“other” (including disseminated BCG infection).
Statistical analysis and ethics approval. The incidence of
adverse reactions was calculated as the number of people who
reported reactions divided by the total number of vaccinees for
whom follow-up information was available. Vaccinees were
stratified by age into 2 groups for analysis: those aged !6
months and those aged 6 months. These age groups were
selected because both age and dose (0.05 mL for infants !6
months and 0.1 mL for older people) are known to influence
the rate of adverse reactions [5, 8, 9]. In this study, “adult
vaccinees” were defined as all vaccinees aged 15 years.
A sample size of 900 vaccinees was calculated to be necessary
to achieve a precision of 2.5% around an expected adverse
reaction incidence of 3% with 95% confidence. Statistical anal-
ysis was performed with SAS version 6.12 (SAS) and Epi Info
version 6 (Centers for Disease Control and Prevention). The
cumulative incidence of adverse reactions for the 2 age groups
was calculated. To compare the groups, RRs and their 95% CIs
were determined for each reaction type, and Fisher’s exact test
was used to ascertain whether the relative risks were significant
and to identify factors associated with an increased risk of
adverse reactions. Continuous variables were analyzed by anal-
ysis of variance.
The study was approved by the Communicable Diseases Net-
work of Australia and New Zealand and by the Australian De-
fence Medical Ethics Committee. Only vaccinees from the Aus-
tralian Defence Force were required to give written consent to
participate in the study.
RESULTS
Study population. Vaccinees were enrolled by BCG providers
from all Australian regions except the state of Queensland.
During November 1998–December 1999, 1246 vaccinees were
enrolled in the study; 918 patients (74%) completed follow-
up. The remaining 328 vaccinees could not be contacted for
follow-up. The majority of these vaccinees, particularly the
members of the Defence Force, were traveling overseas for ex-
tended periods. One infant died of sudden infant death syn-
drome within 5 weeks of vaccination; because of communi-
cation difficulties and the remote location of the infant, no
other information was available. Although the proportion of
eligible vaccinees was unknown, patients lost to follow-up were
not significantly different from those who completed the study
in terms of age ( ), sex ( ), or ethnicity ( ).Pp .9 Pp .2 Pp .1
Most vaccinations (63%) were administered in hospital-based
or Defence Force clinics (which are listed in the Acknowledg-
ments). The remaining vaccinations were given in community
health clinics (19%); student health centers (10%); and in gen-
eral practice, council, or travelers’ vaccination clinics (8%). The
numbers of vaccinees from each region were as follows: New
South Wales, 122; Victoria, 109; Western Australia, 98; South
Australia, 113; Australian Capital Territory, 241; Northern Ter-
ritory, 185; and Tasmania, 50.
Vaccinees ranged in age from 1 day to 54 years. Among the
414 infants aged !6 months, 74% were neonates (28 days
old), and 90% were Aboriginal or Asian (table 1). Of the 504
vaccinees aged 6 months, 91% were adults (15 years). That
the majority (80%) of vaccinated adults were of European de-
scent and were aged 15–24 years reflects the large proportion
of vaccinations given to Defence Force personnel and to stu-
dents training in health care–related occupations. Although the
overall male:female ratio for adult vaccinees was 1.7:1 (table
1), for Defence Force personnel, the ratio was 3:1. Conversely,
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Table 1. Demographic characteristics of 918 vaccinees who received BCG.
Characteristic
No. of vaccinees, by age groupa



















Male 188 138 50 296 24 3 199 49 14 7
Female 222 169 53 206 14 2 135 40 10 5
Country of birth
Australia 414 310 104 464 37 5 310 78 23 11
Other 0 0 0 40 1 0 26 11 1 1
Ethnicity
European 20 13 7 421 13 4 292 78 22 12
Aboriginal 250 238 12 3 1 0 2 0 0 0
Asian 121 44 77 45 14 0 22 7 2 0
Other 20 13 7 17 8 1 6 2 0 0
Indication for BCG
ADF
Male — — — 198 — — 156 35 6 1
Female — — — 65 — — 61 4 0 0
HCW or student
Male — — — 34 — — 30 3 1 0
Female — — — 52 — — 40 11 0 1
Otherb
Male 188 138 50 64 24 3 13 11 7 6
Female 222 169 53 89 14 2 34 25 10 4
NOTE. ADF, Australian Defense Force; HCW, health care worker.
a Demographic data not available for all age categories.
b Indication for BCG vaccination includes living in a region with a high incidence of tuberculosis or travel to country of high prevalence.
among those training in areas of health care, women outnum-
bered men (female:male ratio 1.5:1).
Of the 504 vaccinees for whom a tuberculin test was indicated
(individuals aged 6 months), 489 (97%) were tested before
vaccination. None was recorded as having a positive test result
(5 mm). Only 13 (1.4%) of 918 had received a previous BCG
vaccination, from 9 to 28 years before their current vaccination.
No vaccinee was known to be immunocompromised.
Concomitant vaccinations (those given within 4 weeks before
BCG vaccination) were administered to 292 vaccinees (32%).
Of these, 234 were infants receiving routine childhood im-
munizations (predominantly hepatitis B vaccine [94%] but,
also, diphtheria-tetanus-pertussis and oral polio vaccine). With
the exception of oral polio vaccine, all infant vaccinations were
administered intramuscularly in the vastus lateralis muscle of
the leg.
Of the infants, 99% received the recommended BCG vaccine
dose of 0.05 mL (dose was not recorded for the remaining 1%).
Of the 503 adults for whom a vaccine dose was recorded, 96%
received 0.1 mL; the remainder received either 0.05 mL or 0.075
mL.
Vaccine batch was documented for 99.6% of subjects. Vac-
cinees received 1 of 4 vaccine batches: 2612-12 (26 vaccinees),
2614-12 (69 vaccinees), 2615-13 (807 vaccinees), and 2616-14
(13 vaccinees). Connaught batch 2615-13 accounted for 90%
of the BCG vaccine distributed in Australia in 1998. The vaccine
batch associated with the earlier regional cluster of adverse
events [6] was not distributed during the study.
In 86% of instances, BCG vaccine was given by a provider
trained in BCG vaccination. A greater proportion (95%) of
providers who vaccinated older individuals were trained, com-
pared with those who vaccinated infants !6 months of age
(76%). All vaccinations were given in the deltoid region of the
arm. Information about injection technique (e.g., whether the
vaccine was inadvertently administered subcutaneously rather
than intradermally) was not recorded.
Adverse reactions. A total of 53 adverse reactions were
reported by 45 (5%) of 916 vaccinees. Most adverse reactions
were mild and self-limiting. There were no reports of dissem-
inated BCG infection. Eleven vaccinees (1%) required attention
from a health care practitioner (table 2).
Injection-site abscesses accounted for 23 (43%) of 53 reac-
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Table 2. Cumulative incidence (%) of adverse reactions after BCG vaccination, by
age group and type of reaction.
Condition
No. (%) of vaccinees, by age group







Abscess 5 (1.2) 18 (3.6) 23 (2.5) 2.96 (1.11–7.90) .02
Lymphadenitis 6 (1.4) 4 (0.8) 10 (1.0) 0.55 (0.16–1.93) .3
Severe local reaction 2 (0.5) 12 (2.4) 14 (1.5) 4.93 (1.11–21.90) .02
Other 2 (0.5) 4 (0.8) 6 (0.7) 1.64 (0.30–8.93) .6
Any reactionb 14 (3.4) 31 (6.2) 45 (4.9) 1.82 (0.98–3.37) .05
a Cumulative incidence of adverse reactions in vaccinees aged 6 months compared with those aged
!6 months.
b Eight vaccinees reported 11 reaction.
tions. The median time to onset was 30 days (range, 4–65 days).
Of the 23 abscesses, 7 required treatment (surgical excision, 2;
antibiotics, 3; and symptomatic treatment, 2). All 16 remaining
abscesses resolved spontaneously.
Lymphadenitis, which was reported by 10 vaccinees (1%)
and involved axillary nodes in 9 vaccinees and cervical nodes
in 1 vaccinee. The onset of lymphadenitis occurred at a median
of 63 days after vaccination (range, 16–87 days). Lymph node,
diameter was 15–30 mm. Most episodes resolved without in-
tervention; however, one infant (aged 3 months) was treated
with antituberculosis therapy (isoniazid and rifampicin).
Severe local reactions comprising pain, redness, or swelling
that lasted 13 days were reported by 14 vaccinees (1.5%) and
accounted for 14 (26%) of 53 reported reactions. No reaction
caused swelling beyond the nearest joint or resulted in hos-
pitalization. Three vaccinees received antibiotic treatment for
severe local reactions.
Another 6 problems categorized as “other” were reported:
pronounced scars ( ), marked redness at the site of in-np 3
jection within 24 h of vaccination ( ), and fever for 2 daysnp 2
after vaccination ( ). None required treatment.np 1
Eight vaccinees reported having 1 1 complication. Types of
reactions reported were as follows: local and other ( ),np 3
abscess and local ( ), and abscess and other ( ).np 4 np 1
The overall incidence of adverse reactions was higher for
older subjects (6.2%) than for infants (3.4%) (table 2). This
difference was attributable to a higher reported rate of injec-
tion-site abscesses (RR, 2.96; 95% CI, 1.11–7.90) and severe
local reactions (RR, 4.93; 95% CI, 1.11–21.90). In vaccinees
aged !6 months, lymphadenitis was more common (1.4%) than
in vaccinees aged 6 months (0.8%) (RR, 1.82; 95% CI,
0.52–6.41), but this difference was not statistically significant.
Factors associated with the development of adverse reac-
tions and their management. Adverse reactions were less
common among older subjects when a previous tuberculin skin
test had been performed (RR, 0.27; 95% CI, 0.09–0.77). Al-
though there was no difference in the overall incidence of re-
actions according to sex, (10 [83%]) of 12 older vaccinees who
reported local reactions were women (RR, 7.18; 95% CI,
1.59–32.45). Older individuals were more likely to receive treat-
ment for their reactions (RR, 4.11; 95% CI, 0.90–18.64; table
3).
Adverse reactions among infants were less likely when the
vaccination was given by trained staff (RR, 0.24; 95% CI,
0.09–0.68). Neither age at vaccination ( ) nor birthPp .61
weight ( ) were significant factors. Among the 310 neo-Pp .54
nates (aged 0–28 days), all adverse reactions occurred in Ab-
original infants (11 [5%] of 238).
The development of an adverse reaction was not significantly
associated with concomitant administration of other vaccines,
previous BCG vaccination, or vaccine batch (table 3). However,
the power of this analysis was limited by small numbers of
prior BCG recipients and receipt of the same vaccine batch in
85% of infants and 90% of older individuals.
DISCUSSION
The incidence of reactions (5%) in this national prospective
study was within the range (0.1%–19%) reported elsewhere [3,
5, 10–14], but differences in the methods used to detect and
define cases make direct comparisons difficult. In particular,
an earlier regional study’s suggestion of a significant increase
(from 0.7% to 3%) in adverse reactions after introduction of
the Connaught vaccine could not be examined because the
previous (CSL) vaccine was no longer in use [6] . Also, the
cases in the earlier study were detected by retrospective review
of patient records with probable incomplete ascertainment. In
the current study, adverse reactions were identified by active
surveillance that used standard case definitions [12]. Although
some complications have been reported to occur up to 2 years
after vaccination, the majority occur within the first 20 weeks
[5].
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Table 3. Factors examined for an association with the development of adverse reactions after BCG
vaccination, by age group.
Factor
No. of vaccinees aged !6 months No. of vaccinees aged 6 months
Total
With any
reaction RR (95% CI) Total
With any
reaction RR (95% CI)
Country of birth — 0.58 (0.21–1.58)
Australia 414 14 464 27
Other 0 0 40 4
Ethnicity 2.4 (0.68–8.47) —
Aboriginal 250 11 3 0
Other 164 3 501 31
Sex 0.85 (0.30–2.37) 1.74 (0.88–3.46)
Female 222 7 206 17
Male 188 7 296 14
Local reaction (by sex) — 7.18 (1.59–32.45)a
Female 222 2 206 10
Male 188 0 296 2
Trained provider 0.24 (0.09–0.68)a 1.70 (0.24–12.0)
Yes 313 6 477 30
No 101 8 27 1
Concomitant vaccine 1.27 (0.43–3.72) 1.38 (0.50–3.77)
Yes 243 9 49 4
No 171 5 455 27
Previous skin test — 0.27 (0.09.0.77)a
Yes 13 0 490 28
No 410 14 14 3
Previous BCG vaccination — 1.37 (0.20–9.17)
Yes 1 0 12 1
No 413 14 492 30
Batch 0.46 (0.15–1.41) 0.60 (0.25–1.89)
Common (2615-13) 350 10 457 27
Other 64 4 47 4
a .P ! .05
Because we followed the vaccinees for 18 weeks, it is unlikely
that adverse reactions were underestimated; however, several
factors may have led to the overestimation of reactions. These
include the method of case ascertainment, publicity concerning
the vaccine, and loss to follow-up of nearly one-quarter of
enrolled vaccinees, assumed that those lost to follow-up ex-
perienced fewer adverse reactions, because it is unlikely that
these vaccinees would fail to report serious adverse reactions
to their provider.
Adverse reaction rates were higher overall for older people
compared with infants. This was in part due to the predomi-
nance (180%) of young adult women who reported local re-
actions. Similar findings have been reported elsewhere [15];
however, the reason for this sex difference remains unknown.
The smaller size of the study and the higher vaccine dose,
relative to weight, for most female subjects may be important;
some studies have suggested that female vaccinees find the local
reaction to BCG cosmetically unacceptable [16]. It is unclear
why older people experienced a higher incidence of injection
site abscesses; however, failure to perform standard Mantoux
testing before vaccination may have been a contributing factor.
These local complications after BCG vaccination highlight the
need for careful consideration of the indication for vaccination
(including interpretation of tuberculin skin test results) and
clear explanation of possible side effects [17].
Vaccination by health care workers untrained in adminis-
tering BCG vaccine is likely to have contributed to the devel-
opment of reactions in vaccinees of all ages [18]. However, this
was most pronounced in infants aged !6 months, 24% of whom
were vaccinated by untrained staff.
Although current Australian guidelines recommend that vac-
cination be done by a trained provider, there is no universal
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training standard. Therefore, it is possible that certain vacci-
nation centers operating without such standards may have been
responsible for the majority of reactions. This analysis was lim-
ited by the overall small overall number of reactions and by
the fact that, for the most part, individual centers vaccinated
homogeneous populations (for example, young adults in the
Defence Force or Aboriginal children).
Providers’ lack of experience in administration of the vaccine
may also have contributed to an increased incidence of reac-
tions. A recent survey [19] in the Australian state of Victoria
found that, because of an increase in the number of registered
vaccinators, 69% of BCG providers vaccinated !25 individuals
per year. Vaccination skills are more likely to be maintained
when the vaccine is given on a regular basis. This is particularly
important for neonatal vaccination, for which there is an in-
creased risk of inadvertent subcutaneous injection. For this
reason, multipuncture percutaneous administration of the vac-
cine has been advocated because the technique is easier to learn
and is associated with a lower incidence of reactions [20].
Certain characteristics of the recently introduced BCG (Con-
naught) vaccine may have accounted for a proportion of ad-
verse reactions. Some strains are known to be more potent
(reactogenic) than others [10, 12]. In particular, BCG vaccines
with lower numbers of culturable particles (and therefore lower
ratios of live to killed bacilli), including Connaught, have been
associated with an increased incidence of adenitis. In 1982 in
Saint Lucia, the incidence of adenitis increased from 4.3% to
9.8% when the supplied vaccine changed from the Glaxo to
the Connaught preparation [21]. After reintroduction of the
Glaxo vaccine, the rate returned to previous levels. Similar find-
ings have been reported in other countries [13]. Other vaccine
properties, such as the composition of vaccine stabilizers, have
been implicated. For instance, monosodium glutamate, used
as the stabilizer in the Connaught preparation, may make re-
constitution more difficult, leading to an increase in reacto-
genicity [12]. Although batch-to-batch variation is known to
occur [6], a relationship between adverse reactions and a spe-
cific batch could not be determined in this study because almost
all subjects received vaccine from the same batch.
The current passive Australian surveillance system for ad-
verse events (Adverse Drug Reactions Advisory Committee, or
ADRAC) identified only 20 BCG adverse reactions during the
period of our study (ADRAC, unpublished data). Underre-
porting and lack of accurate denominator data limit the use-
fulness of passive systems in determining vaccine safety. Active
surveillance of adverse events after vaccination is not conducted
routinely in Australia but has been previously conducted in
specific instances, such as the 1998 Measles Control Campaign
[22]. Although there are limitations associated with prospective
studies of adverse events, such as the long delay before results
become known and the loss to follow-up (for example, people
vaccinated before traveling overseas, as in the present study),
prospective studies remain valuable public health tools. In Aus-
tralia, where claims (based on a case report [23]) of significant
problems after BCG vaccination, attracted considerable media
attention, data from our study were able to put such claims
into perspective.
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